社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
hui1234567
IP属地：未知
+关注
帖子 · 14
帖子 · 14
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
hui1234567
hui1234567
·
2021-12-13
like pls
Visa Warns It Will Crack Down On Cannabis Retailers' Use Of Cashless ATM Payment 'Scheme'
The burgeoning recreational marijuana industry – illegal at the federal level and in some 18 U.S. st
Visa Warns It Will Crack Down On Cannabis Retailers' Use Of Cashless ATM Payment 'Scheme'
看
1,916
回复
1
点赞
1
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-09-14
nice
非常抱歉，此主贴已删除
看
990
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-08-07
trump
看
1,266
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-08-07
edmund
Here’s another sign the bull market is near a peak, and this one bears watching
S&P 500 sectors’ relative strength rankings are flashing red. The U.S. stock market is nearing a to
Here’s another sign the bull market is near a peak, and this one bears watching
看
1,064
回复
1
点赞
3
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-08-04
be hd ic
看
974
回复
评论
点赞
1
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-08-04
finish com
Eli Lilly Earnings Missed Expectations. Why the Stock Is Soaring
Drug giant Eli Lilly reported weaker-than-expected earnings but the stock is soaring. Eli Lilly repo
Eli Lilly Earnings Missed Expectations. Why the Stock Is Soaring
看
1,183
回复
1
点赞
2
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-07-21
nice
Revolut Becomes UK's Biggest Unicorn
Having managed to raise $800 million in a funding round led by Softbank's Vision Fund and Tiger Glob
Revolut Becomes UK's Biggest Unicorn
看
1,222
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-07-20
nice
非常抱歉，此主贴已删除
看
1,928
回复
1
点赞
2
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-07-20
nice
非常抱歉，此主贴已删除
看
1,320
回复
评论
点赞
2
编组 21备份 2
分享
举报
hui1234567
hui1234567
·
2021-07-16
awesome
No evidence yet that it’s time for a 3rd booster, says former FDA director
KEY POINTS There’s not enough evidence that booster vaccines are needed for now, said Norman Baylor
No evidence yet that it’s time for a 3rd booster, says former FDA director
看
1,039
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4087899267516000","uuid":"4087899267516000","gmtCreate":1624797271993,"gmtModify":1624845920848,"name":"hui1234567","pinyin":"hui1234567","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":10,"tweetSize":14,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":604539029,"gmtCreate":1639409423389,"gmtModify":1639410313049,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604539029","repostId":"1136475604","repostType":4,"repost":{"id":"1136475604","kind":"news","pubTimestamp":1639405387,"share":"https://www.laohu8.com/m/news/1136475604?lang=&edition=full","pubTime":"2021-12-13 22:23","market":"us","language":"en","title":"Visa Warns It Will Crack Down On Cannabis Retailers' Use Of Cashless ATM Payment 'Scheme'","url":"https://stock-news.laohu8.com/highlight/detail?id=1136475604","media":"Benzinga","summary":"The burgeoning recreational marijuana industry – illegal at the federal level and in some 18 U.S. st","content":"<p>The burgeoning recreational marijuana industry – illegal at the federal level and in some 18 U.S. states – has faced multiple challenges throughout the years, mostly because of the Schedule 1 status of the cannabis plant.</p>\n<p><b>The biggest problem? Banking, of course.</b></p>\n<p>As in life, <b>retailers have had to find a way to work around the system</b>. Some cannabis merchants have begun using cashless ATMs to bypass limitations on the types of sales payment cards they can legally accept.</p>\n<p>One of the largest payment processors in the world, <b>Visa Inc.</b> (NYSE:V) <b>recently issued a compliance memo to customers warning them that incorrectly coding point-of-sale transactions via cashless ATMs could be penalized or punished by unspecified enforcement procedure</b>, reported Marijuana Moment.</p>\n<p>Visa’s warning comes <b>on the heels of the marijuana banking reform bill that was recently</b> <b>chopped from Congress’ defense bill.</b> The latest version of the Congressional defense bill left out several key provisions that were in the House-approved <b>National Defense Authorization Act</b>(NDAA), including the much-anticipated <b>marijuana banking reform</b> known as the <b>Secure and Fair Enforcement (SAFE) Banking Act</b>, which would protect banking and financial institutions that work with state-legal cannabis companies.</p>\n<p><b>Aware Of A Scheme</b></p>\n<p>Visa’s memo from Dec. 2 obtained by Marijuana Moment revealed that <b>the company is “aware of a scheme”</b>in which retailers are utilizing cashless ATMs to avoid limitations on the types of sales for which payment cards are allowed to be used.</p>\n<p>“Cashless ATMs are POS devices driven by payment applications that mimic standalone ATMs. However, no cash disbursements are made to cardholders,” the memo clarified. “Instead, the devices are used for purchase transactions, which are miscoded as ATM cash disbursements. Purchase amounts are often rounded up to create the appearance of a cash disbursement.”</p>\n<p>Although the Visa directive does not specifically mention cannabis, it highlights that cashless ATMs (also called reverse ATMs) “are primarily marketed to merchant types that are unable to obtain payment services—whether due to the Visa Rules, the rules of other networks, or legal or regulatory prohibitions,” a category that covers marijuana businesses.</p>\n<p><b>Nathaniel Gurien</b>, CEO of <b>Fincann,</b>which provides financial services to cannabis businesses, estimates that <b>thousands of marijuana retailers in the U.S. rely on this scheme.</b></p>\n<p><b>A Desperate Move With Catastrophic Potential</b></p>\n<p>“What keeps me up at night is that when, not if one or more eager assistant U.S. attorneys with their eye on advancement sinks their teeth into this, it <b>has the catastrophic potential to derail our industry’s momentum and inflict great damage</b>,” Gurien told the outlet.</p>\n<p>While it remains clear that marijuana retailers are in an untenable situation – having no access to banking services – they should be aware that<b> relying on the use of cashless ATMs can endanger their operations.</b></p>\n<p>Corporate and banking compliance lawyer <b>Kasim Carbide</b> noted that violating Visa's regulations “<b>may result in a disciplinary action against the Merchant, as well as a potential fine of $200,000 or $2,500 per day</b> (which can be retroactively applied [sic] to and from the first day of noncompliance), <b>and termination of the Merchant’s account</b>.”</p>\n<p>What’s more, according to the <b>Chicago Bar Association</b>, miscoding cannabis sales is not only a violation of payment processors' (in this case Visa’s) policies but a <b>“violation of federal law as well.”</b></p>\n<p><b>Confused Yet?</b></p>\n<p>To exacerbate an already complicated situation,<b> Jessica Billingsley</b>, CEO of cannabis technology company Akerna (NASDAQ:KERN) pointed out that there are <b>probably many businesses that are unaware that cashless ATM practice is illegal.</b></p>\n<p>“With the number of unique complexities and challenges the cannabis industry faces, many operators don’t understand that they have been sold misrepresented products that may not be legal,” Billingsley said in a statement. “The work of a few bad actors cannot undermine the important legal work the majority of ancillary providers have been doing.”</p>\n<p><b>Many cannabis advocates reacted to Visa's statement, arguing that such a large company should support marijuana retailers instead of placing obstacles in their paths.</b></p>\n<p>“It is unfortunate that Visa is unwilling to work with the cannabis industry, which is legal in dozens of states and represents billions of dollars in economic activity, at a time when this country needs all the financial options it can use,” said <b>Morgan Fox</b>, media relations director for the National Cannabis Industry Association. “But it is even worse that they are trying to discourage alternative solutions that are primarily utilized by small businesses to protect themselves and their customers from theft and violent crime.”</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Visa Warns It Will Crack Down On Cannabis Retailers' Use Of Cashless ATM Payment 'Scheme'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVisa Warns It Will Crack Down On Cannabis Retailers' Use Of Cashless ATM Payment 'Scheme'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 22:23 GMT+8 <a href=https://www.benzinga.com/markets/cannabis/21/12/24568435/visa-warns-it-will-crack-down-on-cannabis-retailers-use-of-cashless-atm-payment-scheme><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The burgeoning recreational marijuana industry – illegal at the federal level and in some 18 U.S. states – has faced multiple challenges throughout the years, mostly because of the Schedule 1 status ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cannabis/21/12/24568435/visa-warns-it-will-crack-down-on-cannabis-retailers-use-of-cashless-atm-payment-scheme\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/markets/cannabis/21/12/24568435/visa-warns-it-will-crack-down-on-cannabis-retailers-use-of-cashless-atm-payment-scheme","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136475604","content_text":"The burgeoning recreational marijuana industry – illegal at the federal level and in some 18 U.S. states – has faced multiple challenges throughout the years, mostly because of the Schedule 1 status of the cannabis plant.\nThe biggest problem? Banking, of course.\nAs in life, retailers have had to find a way to work around the system. Some cannabis merchants have begun using cashless ATMs to bypass limitations on the types of sales payment cards they can legally accept.\nOne of the largest payment processors in the world, Visa Inc. (NYSE:V) recently issued a compliance memo to customers warning them that incorrectly coding point-of-sale transactions via cashless ATMs could be penalized or punished by unspecified enforcement procedure, reported Marijuana Moment.\nVisa’s warning comes on the heels of the marijuana banking reform bill that was recently chopped from Congress’ defense bill. The latest version of the Congressional defense bill left out several key provisions that were in the House-approved National Defense Authorization Act(NDAA), including the much-anticipated marijuana banking reform known as the Secure and Fair Enforcement (SAFE) Banking Act, which would protect banking and financial institutions that work with state-legal cannabis companies.\nAware Of A Scheme\nVisa’s memo from Dec. 2 obtained by Marijuana Moment revealed that the company is “aware of a scheme”in which retailers are utilizing cashless ATMs to avoid limitations on the types of sales for which payment cards are allowed to be used.\n“Cashless ATMs are POS devices driven by payment applications that mimic standalone ATMs. However, no cash disbursements are made to cardholders,” the memo clarified. “Instead, the devices are used for purchase transactions, which are miscoded as ATM cash disbursements. Purchase amounts are often rounded up to create the appearance of a cash disbursement.”\nAlthough the Visa directive does not specifically mention cannabis, it highlights that cashless ATMs (also called reverse ATMs) “are primarily marketed to merchant types that are unable to obtain payment services—whether due to the Visa Rules, the rules of other networks, or legal or regulatory prohibitions,” a category that covers marijuana businesses.\nNathaniel Gurien, CEO of Fincann,which provides financial services to cannabis businesses, estimates that thousands of marijuana retailers in the U.S. rely on this scheme.\nA Desperate Move With Catastrophic Potential\n“What keeps me up at night is that when, not if one or more eager assistant U.S. attorneys with their eye on advancement sinks their teeth into this, it has the catastrophic potential to derail our industry’s momentum and inflict great damage,” Gurien told the outlet.\nWhile it remains clear that marijuana retailers are in an untenable situation – having no access to banking services – they should be aware that relying on the use of cashless ATMs can endanger their operations.\nCorporate and banking compliance lawyer Kasim Carbide noted that violating Visa's regulations “may result in a disciplinary action against the Merchant, as well as a potential fine of $200,000 or $2,500 per day (which can be retroactively applied [sic] to and from the first day of noncompliance), and termination of the Merchant’s account.”\nWhat’s more, according to the Chicago Bar Association, miscoding cannabis sales is not only a violation of payment processors' (in this case Visa’s) policies but a “violation of federal law as well.”\nConfused Yet?\nTo exacerbate an already complicated situation, Jessica Billingsley, CEO of cannabis technology company Akerna (NASDAQ:KERN) pointed out that there are probably many businesses that are unaware that cashless ATM practice is illegal.\n“With the number of unique complexities and challenges the cannabis industry faces, many operators don’t understand that they have been sold misrepresented products that may not be legal,” Billingsley said in a statement. “The work of a few bad actors cannot undermine the important legal work the majority of ancillary providers have been doing.”\nMany cannabis advocates reacted to Visa's statement, arguing that such a large company should support marijuana retailers instead of placing obstacles in their paths.\n“It is unfortunate that Visa is unwilling to work with the cannabis industry, which is legal in dozens of states and represents billions of dollars in economic activity, at a time when this country needs all the financial options it can use,” said Morgan Fox, media relations director for the National Cannabis Industry Association. “But it is even worse that they are trying to discourage alternative solutions that are primarily utilized by small businesses to protect themselves and their customers from theft and violent crime.”","news_type":1,"symbols_score_info":{"V":0.9}},"isVote":1,"tweetType":1,"viewCount":1916,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886313834,"gmtCreate":1631550304629,"gmtModify":1631890241975,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/886313834","repostId":"1153154616","repostType":4,"isVote":1,"tweetType":1,"viewCount":990,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891349501,"gmtCreate":1628341054203,"gmtModify":1631890241977,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"trump","listText":"trump","text":"trump","images":[{"img":"https://static.tigerbbs.com/54d7ecdbfff0a7bde2969f168e6cb96c","width":"1125","height":"1974"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891349501","isVote":1,"tweetType":1,"viewCount":1266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":891349160,"gmtCreate":1628340976550,"gmtModify":1631890241977,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"edmund","listText":"edmund","text":"edmund","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/891349160","repostId":"1124487485","repostType":4,"repost":{"id":"1124487485","kind":"news","pubTimestamp":1628258241,"share":"https://www.laohu8.com/m/news/1124487485?lang=&edition=full","pubTime":"2021-08-06 21:57","market":"us","language":"en","title":"Here’s another sign the bull market is near a peak, and this one bears watching","url":"https://stock-news.laohu8.com/highlight/detail?id=1124487485","media":"MarketWatch","summary":"S&P 500 sectors’ relative strength rankings are flashing red.\n\nThe U.S. stock market is nearing a to","content":"<blockquote>\n <b>S&P 500 sectors’ relative strength rankings are flashing red.</b>\n</blockquote>\n<p>The U.S. stock market is nearing a top, according to a leading indicator that is based on the trailing three-month returns of the S&P 500 SPX, +0.08% sectors.</p>\n<p>Over the three months prior to past bull-market tops, a fairly predictable pattern emerged of which sectors performed best and which fared worst. Currently, a ranking of the sectors’ recent relative strength lines up fairly close with that pattern.</p>\n<p>This is a big change since mid-May when, as I reported, this leading indicator was not detecting any signs of imminent trouble. The sectors with the best trailing three-month returns at that time were not those that typically lead the market prior to tops, and the sectors with the worst trailing three-month returns were not those that typically lag.</p>\n<p>Now, in contrast, there is a distinct correlation between the sectors’ relative strength ranking and the typical pattern that appeared in past tops.</p>\n<p>According to research conducted by Ned Davis Research, Utilities, Energy and Financials are the S&P 500 sectors that have performed the worst, on average, in the final three months of all bull markets since 1970. As is clear in the chart below, these three sectors now are at or near the bottom in a ranking of trailing three-month returns.</p>\n<p><img src=\"https://static.tigerbbs.com/8465aa12910238871b10168546466b1f\" tg-width=\"2100\" tg-height=\"1272\" width=\"100%\" height=\"auto\"></p>\n<p>In contrast, according to Ned Davis Research, Consumer Staples, Health Care and Consumer Discretionary are the sectors that have performed the best, on average, over the three months prior to past bull market tops. As the chart shows, these three have performed relatively well over the past three months.</p>\n<p>To quantify how much the sector relative strength rankings have shifted in a bearish direction, consider the correlation coefficients that I calculated. This statistic ranges from a high of 1.0 (which would mean that there is a perfect one-to-one correspondence between a ranking of the sectors’ recent returns and the historical pattern) to minus 1.0 (which would mean a perfectly inverse correlation). A coefficient of zero would mean that there is no detectable relationship.</p>\n<p>In mid-May, this coefficient stood at a significantly negative minus 0.66. Today, in contrast, it is a positive 0.67. This latest reading is one of the higher coefficients I’ve seen from my periodic monitoring of this indicator.</p>\n<p>Needless to say, neither this (nor any indicator, for that matter) is guaranteed to work. One time that it was accurate was in April 2015, when my column on this indicator ran under the headline “leading indicators signal a market top.” A bear market began one month later, according to the bear-market calendar maintained by Ned Davis Research. The correlation coefficient between the relative strength ranking that then prevailed and the historical pattern stood at 0.43; the current reading is higher and so even more bearish.</p>\n<p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s another sign the bull market is near a peak, and this one bears watching</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s another sign the bull market is near a peak, and this one bears watching\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:57 GMT+8 <a href=https://www.marketwatch.com/story/heres-another-sign-the-bull-market-is-near-a-peak-and-this-one-bears-watching-11628233932?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>S&P 500 sectors’ relative strength rankings are flashing red.\n\nThe U.S. stock market is nearing a top, according to a leading indicator that is based on the trailing three-month returns of the S&P 500...</p>\n\n<a href=\"https://www.marketwatch.com/story/heres-another-sign-the-bull-market-is-near-a-peak-and-this-one-bears-watching-11628233932?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/heres-another-sign-the-bull-market-is-near-a-peak-and-this-one-bears-watching-11628233932?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124487485","content_text":"S&P 500 sectors’ relative strength rankings are flashing red.\n\nThe U.S. stock market is nearing a top, according to a leading indicator that is based on the trailing three-month returns of the S&P 500 SPX, +0.08% sectors.\nOver the three months prior to past bull-market tops, a fairly predictable pattern emerged of which sectors performed best and which fared worst. Currently, a ranking of the sectors’ recent relative strength lines up fairly close with that pattern.\nThis is a big change since mid-May when, as I reported, this leading indicator was not detecting any signs of imminent trouble. The sectors with the best trailing three-month returns at that time were not those that typically lead the market prior to tops, and the sectors with the worst trailing three-month returns were not those that typically lag.\nNow, in contrast, there is a distinct correlation between the sectors’ relative strength ranking and the typical pattern that appeared in past tops.\nAccording to research conducted by Ned Davis Research, Utilities, Energy and Financials are the S&P 500 sectors that have performed the worst, on average, in the final three months of all bull markets since 1970. As is clear in the chart below, these three sectors now are at or near the bottom in a ranking of trailing three-month returns.\n\nIn contrast, according to Ned Davis Research, Consumer Staples, Health Care and Consumer Discretionary are the sectors that have performed the best, on average, over the three months prior to past bull market tops. As the chart shows, these three have performed relatively well over the past three months.\nTo quantify how much the sector relative strength rankings have shifted in a bearish direction, consider the correlation coefficients that I calculated. This statistic ranges from a high of 1.0 (which would mean that there is a perfect one-to-one correspondence between a ranking of the sectors’ recent returns and the historical pattern) to minus 1.0 (which would mean a perfectly inverse correlation). A coefficient of zero would mean that there is no detectable relationship.\nIn mid-May, this coefficient stood at a significantly negative minus 0.66. Today, in contrast, it is a positive 0.67. This latest reading is one of the higher coefficients I’ve seen from my periodic monitoring of this indicator.\nNeedless to say, neither this (nor any indicator, for that matter) is guaranteed to work. One time that it was accurate was in April 2015, when my column on this indicator ran under the headline “leading indicators signal a market top.” A bear market began one month later, according to the bear-market calendar maintained by Ned Davis Research. The correlation coefficient between the relative strength ranking that then prevailed and the historical pattern stood at 0.43; the current reading is higher and so even more bearish.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":1064,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807120091,"gmtCreate":1628007749513,"gmtModify":1631890241982,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"be hd ic","listText":"be hd ic","text":"be hd ic","images":[{"img":"https://static.tigerbbs.com/fc7555123d32840e8935a8e6eee3a064","width":"1125","height":"2249"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807120091","isVote":1,"tweetType":1,"viewCount":974,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807167198,"gmtCreate":1628007708114,"gmtModify":1631890241984,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"finish com","listText":"finish com","text":"finish com","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/807167198","repostId":"1124475692","repostType":4,"repost":{"id":"1124475692","kind":"news","pubTimestamp":1628003267,"share":"https://www.laohu8.com/m/news/1124475692?lang=&edition=full","pubTime":"2021-08-03 23:07","market":"us","language":"en","title":"Eli Lilly Earnings Missed Expectations. Why the Stock Is Soaring","url":"https://stock-news.laohu8.com/highlight/detail?id=1124475692","media":"Barron's","summary":"Drug giant Eli Lilly reported weaker-than-expected earnings but the stock is soaring.\nEli Lilly repo","content":"<p>Drug giant Eli Lilly reported weaker-than-expected earnings but the stock is soaring.</p>\n<p>Eli Lilly reported a year-over-year leap in second-quarter sales, but much of that rise resulted from the world’s restocking since 2020 lockdowns. Sales still grew a respectable 12%, after adjusting for Covid-19’s impact, while earnings matched Wall Street forecasts.</p>\n<p>Investors were satisfied. Lilly (ticker: LLY) stock is up 4% to $256.53 in Tuesday morning trading, while the Dow Jones Industrial Average is up 0.1% and the S&P 500 is flat.</p>\n<p>All told, Lilly’s second-quarter revenue jumped 23% to $6.7 billion. That’s slightly better than the $6.6 billion consensus forecast among analysts tallied at Sentieo.com. The Indianapolis-based company enjoyed strong volume growth. The strong year-over-year comparison benefited from the subdued level of June 2020 business in the Covid lockdown, which sapped $250 million from last year’s quarter, by Lilly estimate. Adjusting for that unusual weakness, as well as one-time benefits in 2021 like the company’s sale of Chinese rights to its erectile dysfunction treatment Cialis, Lilly said that second-quarter sales grew 12%.</p>\n<p>The company highlighted the strong growth of newer products, like diabetes drug Trulicity, heart drug Jardiance, and psoriasis treatment Taltz. Before year-end 2021, it hopes to file a marketing application for its investigational treatment for Alzheimer’s disease, donanemab. The Food and Drug Administration’s surprise approval of the Alzheimer’s treatment Aduhelm from Biogen (BIIB) has raised investor expectations for other candidates like Lilly’s.</p>\n<p>Earnings in the second quarter were $1.4 billion, or $1.53 per share. Adjusting for noncash and one-time accruals, Lilly says EPS were $1.83, which represented growth of about 30% from the adjusted number for the year-ago second quarter.</p>\n<p>Antibody treatments for Covid have been a boost to Lilly stock in recent quarters. Second-quarter revenue from those treatments was $149 million. The appearance of variant strains of the Covid-causing SARS-CoV-2 coronavirus is a problem for custom-crafted antibody treatments, however. While Lilly says that its two authorized antibody products show laboratory effectiveness against the virus’ worrisome Delta variant, the U.S. government stopped shipments of the Lilly antibodies in June on evidence that they don’t neutralize the Beta and Gamma variants.</p>\n<p>So Lilly is writing down the value of some antibody inventories, and the write-down led it to revise its earnings guidance for the 2021 year. Profits this year will come in around a midpoint of about $6.83 a share, says Lilly, instead of the previously guided midpoint of $7.13. Apart from the write-down, and other noncash adjustments, however, the midpoint forecast is unchanged, at $7.90 a share.</p>\n<p>Lilly gained 4% in morning trading, reached record high.<img src=\"https://static.tigerbbs.com/dfc51bbb6cd284c0017ede89c2bc6240\" tg-width=\"946\" tg-height=\"633\" width=\"100%\" height=\"auto\"></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Earnings Missed Expectations. Why the Stock Is Soaring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Earnings Missed Expectations. Why the Stock Is Soaring\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 23:07 GMT+8 <a href=https://www.barrons.com/articles/eli-lilly-stock-earnings-sales-51628001381?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Drug giant Eli Lilly reported weaker-than-expected earnings but the stock is soaring.\nEli Lilly reported a year-over-year leap in second-quarter sales, but much of that rise resulted from the world’s ...</p>\n\n<a href=\"https://www.barrons.com/articles/eli-lilly-stock-earnings-sales-51628001381?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.barrons.com/articles/eli-lilly-stock-earnings-sales-51628001381?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124475692","content_text":"Drug giant Eli Lilly reported weaker-than-expected earnings but the stock is soaring.\nEli Lilly reported a year-over-year leap in second-quarter sales, but much of that rise resulted from the world’s restocking since 2020 lockdowns. Sales still grew a respectable 12%, after adjusting for Covid-19’s impact, while earnings matched Wall Street forecasts.\nInvestors were satisfied. Lilly (ticker: LLY) stock is up 4% to $256.53 in Tuesday morning trading, while the Dow Jones Industrial Average is up 0.1% and the S&P 500 is flat.\nAll told, Lilly’s second-quarter revenue jumped 23% to $6.7 billion. That’s slightly better than the $6.6 billion consensus forecast among analysts tallied at Sentieo.com. The Indianapolis-based company enjoyed strong volume growth. The strong year-over-year comparison benefited from the subdued level of June 2020 business in the Covid lockdown, which sapped $250 million from last year’s quarter, by Lilly estimate. Adjusting for that unusual weakness, as well as one-time benefits in 2021 like the company’s sale of Chinese rights to its erectile dysfunction treatment Cialis, Lilly said that second-quarter sales grew 12%.\nThe company highlighted the strong growth of newer products, like diabetes drug Trulicity, heart drug Jardiance, and psoriasis treatment Taltz. Before year-end 2021, it hopes to file a marketing application for its investigational treatment for Alzheimer’s disease, donanemab. The Food and Drug Administration’s surprise approval of the Alzheimer’s treatment Aduhelm from Biogen (BIIB) has raised investor expectations for other candidates like Lilly’s.\nEarnings in the second quarter were $1.4 billion, or $1.53 per share. Adjusting for noncash and one-time accruals, Lilly says EPS were $1.83, which represented growth of about 30% from the adjusted number for the year-ago second quarter.\nAntibody treatments for Covid have been a boost to Lilly stock in recent quarters. Second-quarter revenue from those treatments was $149 million. The appearance of variant strains of the Covid-causing SARS-CoV-2 coronavirus is a problem for custom-crafted antibody treatments, however. While Lilly says that its two authorized antibody products show laboratory effectiveness against the virus’ worrisome Delta variant, the U.S. government stopped shipments of the Lilly antibodies in June on evidence that they don’t neutralize the Beta and Gamma variants.\nSo Lilly is writing down the value of some antibody inventories, and the write-down led it to revise its earnings guidance for the 2021 year. Profits this year will come in around a midpoint of about $6.83 a share, says Lilly, instead of the previously guided midpoint of $7.13. Apart from the write-down, and other noncash adjustments, however, the midpoint forecast is unchanged, at $7.90 a share.\nLilly gained 4% in morning trading, reached record high.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":1183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176397829,"gmtCreate":1626859838961,"gmtModify":1631890241986,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176397829","repostId":"1192426531","repostType":4,"repost":{"id":"1192426531","kind":"news","pubTimestamp":1626858599,"share":"https://www.laohu8.com/m/news/1192426531?lang=&edition=full","pubTime":"2021-07-21 17:09","market":"uk","language":"en","title":"Revolut Becomes UK's Biggest Unicorn","url":"https://stock-news.laohu8.com/highlight/detail?id=1192426531","media":"zerohedge","summary":"Having managed to raise $800 million in a funding round led by Softbank's Vision Fund and Tiger Glob","content":"<p><b>Having managed to raise $800 million in a funding round led by Softbank's Vision Fund and Tiger Global Management, UK-based fintech company Revolut is now valued at $33 billion</b>, making it the biggest 'unicorn' in the country as well as the highest-valued fintech company.</p>\n<p>As reported by Reuters, \"Revolut has won more than 16 million customers with products including foreign exchange, stock trading and cryptocurrencies, undercutting mainstream banks' prices.\"</p>\n<p>However,as Statista's Martin Armstrong notes,<i><b>\"it has yet to translate that rapid growth into profitability, with its annual losses doubling last financial year on investment in risk controls.\"</b></i></p>\n<p>Second on the list of the UK's most valuable unicorns, as compiled byCB Insights, is another fintech company - checkout.com - which reached its $15 billion valuation after raising $450 million at the beginning of the year, again led by Tiger Global Management.</p>\n<p><img src=\"https://static.tigerbbs.com/63080ab1bf0f6d0624138655b5f695b2\" tg-width=\"1200\" tg-height=\"1200\" width=\"100%\" height=\"auto\"><i>You will find more infographics atStatista</i></p>\n<p><b>Checkout and Revolut are now up there with the most valuable fintech companies in the world.</b></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolut Becomes UK's Biggest Unicorn</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolut Becomes UK's Biggest Unicorn\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 17:09 GMT+8 <a href=https://www.zerohedge.com/markets/revolut-becomes-uks-biggest-unicorn><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Having managed to raise $800 million in a funding round led by Softbank's Vision Fund and Tiger Global Management, UK-based fintech company Revolut is now valued at $33 billion, making it the biggest ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/revolut-becomes-uks-biggest-unicorn\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.zerohedge.com/markets/revolut-becomes-uks-biggest-unicorn","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192426531","content_text":"Having managed to raise $800 million in a funding round led by Softbank's Vision Fund and Tiger Global Management, UK-based fintech company Revolut is now valued at $33 billion, making it the biggest 'unicorn' in the country as well as the highest-valued fintech company.\nAs reported by Reuters, \"Revolut has won more than 16 million customers with products including foreign exchange, stock trading and cryptocurrencies, undercutting mainstream banks' prices.\"\nHowever,as Statista's Martin Armstrong notes,\"it has yet to translate that rapid growth into profitability, with its annual losses doubling last financial year on investment in risk controls.\"\nSecond on the list of the UK's most valuable unicorns, as compiled byCB Insights, is another fintech company - checkout.com - which reached its $15 billion valuation after raising $450 million at the beginning of the year, again led by Tiger Global Management.\nYou will find more infographics atStatista\nCheckout and Revolut are now up there with the most valuable fintech companies in the world.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171708147,"gmtCreate":1626761328789,"gmtModify":1631890241995,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/171708147","repostId":"1135145685","repostType":4,"isVote":1,"tweetType":1,"viewCount":1928,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171703615,"gmtCreate":1626761185837,"gmtModify":1631890241998,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171703615","repostId":"2152402666","repostType":4,"isVote":1,"tweetType":1,"viewCount":1320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170804527,"gmtCreate":1626417218369,"gmtModify":1631890242008,"author":{"id":"4087899267516000","authorId":"4087899267516000","name":"hui1234567","avatar":"https://static.tigerbbs.com/f1ef5eb26f8ef01d38bcf417264003a1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087899267516000","authorIdStr":"4087899267516000"},"themes":[],"htmlText":"awesome ","listText":"awesome ","text":"awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170804527","repostId":"1176367685","repostType":4,"repost":{"id":"1176367685","kind":"news","pubTimestamp":1626412781,"share":"https://www.laohu8.com/m/news/1176367685?lang=&edition=full","pubTime":"2021-07-16 13:19","market":"us","language":"en","title":"No evidence yet that it’s time for a 3rd booster, says former FDA director","url":"https://stock-news.laohu8.com/highlight/detail?id=1176367685","media":"cnbc","summary":"KEY POINTS\n\nThere’s not enough evidence that booster vaccines are needed for now, said Norman Baylor","content":"<div>\n<p>KEY POINTS\n\nThere’s not enough evidence that booster vaccines are needed for now, said Norman Baylor, president and chief executive officer of Biologics Consulting.\n“We’re just not there yet … we don’...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/16/not-prudent-to-deploy-vaccine-boosters-at-this-point-ex-fda-director.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>No evidence yet that it’s time for a 3rd booster, says former FDA director</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNo evidence yet that it’s time for a 3rd booster, says former FDA director\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 13:19 GMT+8 <a href=https://www.cnbc.com/2021/07/16/not-prudent-to-deploy-vaccine-boosters-at-this-point-ex-fda-director.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nThere’s not enough evidence that booster vaccines are needed for now, said Norman Baylor, president and chief executive officer of Biologics Consulting.\n“We’re just not there yet … we don’...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/16/not-prudent-to-deploy-vaccine-boosters-at-this-point-ex-fda-director.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/07/16/not-prudent-to-deploy-vaccine-boosters-at-this-point-ex-fda-director.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1176367685","content_text":"KEY POINTS\n\nThere’s not enough evidence that booster vaccines are needed for now, said Norman Baylor, president and chief executive officer of Biologics Consulting.\n“We’re just not there yet … we don’t have the evidence that it’s time for a booster,” he said, adding that in future, there could be new variants that render current vaccines ineffective or much less effective.\nPfizer said on July 8 that it is developing a Covid booster shot, or third dose, to target the highly transmissible delta variant.\n\nThere isn’t enough evidence right now to show that booster shots for Covid vaccines are needed, according to a former FDA director.\n“Being prepared to make boosters is a good thing, but we really don’t have … evidence, at least in the United States, where we’re seeing vaccine failures or we’re seeing waning in immunity, such that it’s time to deploy a booster,” said Norman Baylor, who was previously with the U.S. Food and Drug Administration’s office of vaccines research and review.\nPharmaceutical firm Pfizerisdeveloping a Covid booster shot, or third dose, to target the highly transmissible delta variant,which has become the dominant strain in many countries including the U.S.\nThe Centers for Disease Control and Prevention and FDA also said last week in a joint statement that“Americans who have been fully vaccinated won’t need a booster dose at this time.”\nPfizer met with U.S. officials on Mondayto make its case for a third shot.\nThe company worked with German companyBioNTechto develop a vaccine that consists of two doses given three weeks apart. It was given emergency use authorization by the World Health Organization in December.\nNo significant vaccine failure\nPfizer and BioNTech pointed to data fromIsrael’s health ministry that said there was decreased effectiveness in their vaccine,in terms of preventing infection and symptomatic disease.\nThe decline in efficacy coincided with the spread of the delta variant and the end of most Covid measures in Israel. The shot remains 93% effective in preventing hospitalizations and serious illness from Covid-19, the ministry reportedly said.\n\n The vaccine failures are really low at this time for the current vaccines that have been deployed. So until that shifts, I don’t think it would be prudent to deploy a booster dose.Norman BaylorBIOLOGICS CONSULTING CEO\n\nBut Baylor, who is currently president and chief executive officer of Biologics Consulting, said close monitoring has not revealed “significant vaccine failures” so far.\n“We’re just not seeing that now,” he told“Street Signs Asia”on Thursday.\nCovid cases are rising in the U.S. again, butdoctors say the increase in cases and hospitalizations are due to the delta variant spreading in unvaccinated populations.\n“The vaccine failures are really low at this time for the current vaccines that have been deployed. So until that shifts, I don’t think it would be prudent to deploy a booster dose,” Baylor said.\nHe said health agencies seem to be in agreement that a third dose is not needed.\n“We’re just not there yet … we don’t have the evidence that it’s time for a booster,” he said, adding that in future, there could be new variants that render current vaccines ineffective or much less effective.\nVaccine inequality\nRicher countries have been able to vaccinate large numbers of their population, while poorer countries lag behind.\nThe issue of vaccine disparity between regions needs to be addressed, Baylor said.\n“A pandemic itself, the definition is that it’s global,” he said, adding that he agrees with the World Health Organization that the crisis needs to be looked at from a global perspective.\n\n Some countries and regions are actually ordering millions of booster doses before other countries have had supplies to vaccinate their health workers and most vulnerable.Tedros Adhanom GhebreyesusDIRECTOR-GENERAL, WORLD HEALTH ORGANIZATION\n\nWHO Director-General Tedros Adhanom Ghebreyesus said Monday thatthe world is “in the midst of a growing two-track pandemic.”\n“Some countries and regions are actually ordering millions of booster doses before other countries have had supplies to vaccinate their health workers and most vulnerable,”he said during a press briefing, adding that the world ismaking “conscious choices” not to protect those who are most in need.\nData suggests the vaccines offer long-lasting immunity against severe and deadly Covid-19, he said.\n“The priority now must be to vaccinate those who have received no doses and protection,” the WHO chief said.\nBiotech companies like Pfizer-BioNTech andModerna, which developed another mRNA vaccine for Covid-19, need to “go all out” to channel supplies to places in need, including through the Covax vaccine distribution alliance, he added.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}